menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Merrimack Dissolution, $15.10 Liquidating Dividend Approved

    BUSINESSWIRE

    Merrimack Anticipated Liquidation Distribution Amount

    BUSINESSWIRE

    Merrimack to Voluntarily Delist, Subject to Dissolution Approval

    BUSINESSWIRE

    Merrimack Receives $225 Million Milestone Payment from Ipsen

    BUSINESSWIRE

    Merrimack Reports Full Year 2023 Financial Results

    BUSINESSWIRE

    Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

    PRESS RELEASE

    Merrimack Reports Third Quarter 2023 Financial Results

    BUSINESSWIRE

    Merrimack Reports Second Quarter 2023 Financial Results

    BUSINESSWIRE

    Merrimack Reports Full Year 2022 Financial Results

    BUSINESSWIRE

    Merrimack Provides Ipsen Report That Onivyde® Regimental Adenocarcinoma

    BUSINESSWIRE

    Merrimack Reports Second Quarter 2022 Financial Results

    BUSINESSWIRE

    Merrimack Reports First Quarter 2022 Financial Results

    BUSINESSWIRE

    Merrimack Reports Full Year 2021 Financial Results

    BUSINESSWIRE

    Statement of changes in beneficial ownership of securities

    PRESS RELEASE

    Merrimack Pharmaceuticals (NASDAQ:MACK) Coverage Initiated at StockNews.com

    MARKETBEAT

    Statement of changes in beneficial ownership of securities

    PRESS RELEASE

    Merrimack Pharmaceuticals (NASDAQ:MACK) Coverage Initiated at StockNews.com

    MARKETBEAT

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.